WindMIL Therapeutics and University of Calif₽☆♣♥ornia, Irvine Announce Collaboration to Coll↑λ≠αect Bone Marrow from Patient≤>$s with GliomasWEDNESDAY, OCTOBER 16, 2019W±§indMIL Therapeutics and the University of Califo ↕→rnia, Irvine (UCI) tδ©↔♥oday announced that the first pa‌≠tients have been identifiedβΩ₩ in an investigator-s< ponsored study for the collection¶  of bone marrow from patients with gliomas. The ≈±↓study will evaluate generating marrow infilt≠¶ ¥rating lymphocytes (MILs™) for these patients thr☆∞ough WindMIL’s propriet‌♦•ary cellular activat↔>£<ion and expansion proc£♦​≈ess. The study is being conducted at UCI.“Patπγ•ients suffering with glioblastoma ar÷₽♦©e in great need of new, promisin✔$§g treatments that might advance the curr䧙♦ent standard of care,” s↕×aid Daniela A. Bota, M㧙D, PhD, director of the UΩ§∑™CI Health Comprehensive Brain Tumor Program,♣≥≥δ senior associate dea​↕≠βn for clinical research, UCI School of Medicine ÷ and clinical director, Ω₹→UCI Sue & Bill Gr÷§γ‍oss Stem Cell Research Center. “The Universit×≤γγy of California, Irv♠π←∏ine is excited to play a k≈±ey role in research that may lead to a cli✘λ®nical trial that enlists the immune sysφ≠‍•tem in novel ways to fight this ter ≠₩πrible disease.”Gliomas are the mosεπt common of the malignant♥☆•≤ brain tumors. Glioblastoma, the ε→​most common glioma, has♥✔​ a five-year survival of less than 5 percent. Ad ♥ditional treatment options are urgentl÷∞y needed for these patients. Adoptiβ$ve immunotherapy is a possγ♠β→ible approach for gliomas and the use★✔♠§ of MILs, a cell therapy that is nβ↔aturally tumor-specific, is one such treatment ¶​←option.The bone marrow $♥λ is a unique niche in the₽₩ immune system to whic™$♥✔h antigen-experienced memory ♦₹<T cells traffic and are then m "aintained. WindMIL has developed a$λ proprietary process to select, activat♠÷e and expand these memory T cells into MI☆₽Ls. Because memory T cells in bone marrow occur ₽±∑≠as a result of the immune system’s¥₹♦γ recognition of tumor antigens, MILs are sp♥¶✔ecifically suited for adoptive cellulπ©☆$ar immunotherapy and are able to directly eradi≠λ​™cate or facilitate eradicatio "÷n of each patient’s unique can∑♠×cer. WindMIL is currently studying MILs in mul£α®tiple myeloma, non-small cel&>•l lung cancer and squamous cell carcinoma o§‌™f the head and neck, and plan→≈s to expand into other solid tumors.“↕ WindMIL is looking forward to working with♥δ the University of California, Irvine on ≠ this exciting project and is optimis®✘ βtic that MILs may offer th→‍e potential to help patients with ©€β​these hard-to-treat diseases,” said Monil Shah, ™$✔'PharmD, MBA, Chief Development•₩→ Officer at WindMIL.information sou≥✘rce:pharma focus AsiaThe original link:h↕ ↓<ttps://www.pharmafocusasia.com/n←φ₽✔ews/windmil-therapeutics-and-♠®₽university-of-california-irviσδ ★ne-announce-collaboration-to-collect-b∏γαone-marrow-from-patients-with-gliomas2019 As≥'ia-pacific pharma IP Lπ♠₽eader Summit: http://en ≥.zenseegroup.com/p/5≠÷ 10934/will be held in ‍ ₹ Beijing  on ™÷✘';November 14-15, and will attract more t‌αhan 500 industry expert$€λs from domestic and foreign pharmaceutical comp♦α‍ anies, biotechnology companies, goδ↔vernments, associations, law fir$∞ms, intellectual property agents and other compa≥✘¶nies to attend.Official registration an ¥"d consultation channels:Conta♦♠φct：AnnPhone: 021-65650305Email：Marketing@zense•™egroup.comhttp://en.zenseegroup.& com/p/510934/